<DOC>
	<DOCNO>NCT03091322</DOCNO>
	<brief_summary>This study design post market clinical follow-up study CE-marked product evaluate AV Opt LV VectorOpt feature respective Edora family pacemaker clinical condition . Furthermore , adverse event evaluate identify residual risk associate use BIOTRONIK Edora family pacemaker . The study design address potential regulatory need clinical data country region cover CE approval .</brief_summary>
	<brief_title>BIO|MASTER.Edora Family Study</brief_title>
	<detailed_description>Study Design - Open-label , prospective , non-randomized , multicenter , international - 13 study site Study Endpoints The follow endpoint define assessed descriptive analysis : 1 . AV Opt feature : The feature 's AV delay recommendation 1. use basis device program least consider clinically acceptable 2. AV delay value choose investigator recommendation rat clinically acceptable . 2 . LV VectorOpt usability use overall score ( category : excellent , good , average , fair , poor ) . 3 . ( S ) ADEs calculation SADE free rate 6-month follow-up</detailed_description>
	<criteria>Standard indication pacemaker therapy cardiac resynchronization therapy Patient able understand nature study ; Patient provide write informed consent ; Patient able willing complete plan followup visit investigational site ; Patient accept Home Monitoring® concept ; Age ≥ 18 year . Any contraindication pacemaker cardiac resynchronization therapy ( whichever applies ) ; Patient receive planned receive epicardial LV lead implant ; Pregnant breastfeeding ; Life expectancy le 6 month ; Participation interventional clinical investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>